Lamictal

Phase 3Small molecule

GSK

Lamictal is one of 134 small molecule programs targeting Bipolar I Disorder. It is currently in Phase 3.

Indications

Total Trials

Active Trials

133

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bipolar I DisorderActive, not recruiting

Trigeminal NeuralgiaActive, not recruiting

SeizureActive, not recruiting

EpilepsyActive, not recruiting

Bipolar I DisorderPhase 3

Active, not recruiting

Trigeminal NeuralgiaPhase 2/Phase 3

Active, not recruiting

SeizurePhase 3

Active, not recruiting

EpilepsyPhase 3

Active, not recruiting

Competition

Competitive Landscape

221 competitors in Epilepsy

#DrugCompanyPhaseTrials

Dayvigo

Eisai

Phase 3

1 2

Depacon

AbbVie

Phase 3

1 3

Zonegran

AAzurity Pharmaceuticals

Phase 3

5 4

Fintepla

IImmedica Pharma AB

Phase 3

4 5

Actemra

Roche

Phase 3

—6

Deltavit

HHyundai Pharmaceutical Co., LTD.

Phase 3

3 7

Narcan

SScienture

Phase 3

1 8

GWP42003-P

Jazz Pharmaceuticals

Phase 3

1 9

Akineton

AbbVie

Phase 3

1 10

Lamictal

GSK

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

LAM7 trials

Bioequivalence Study for Lamotrigine Tablets 200 mg Under Fasting Condition

Completed·—·Phase 1·NCT01513720·20 enrolled

Bioequivalence Study for Lamotrigine Tablets 200 mg Under Fed Condition

Completed·—·Phase 1·NCT01513681·20 enrolled

Fasting Study of Lamotrigine Tablets 25 mg to Lamictal® Tablets 25 mg

Completed· Mylan Pharmaceuticals Inc logo

Mylan Pharmaceuticals Inc·Phase 1·NCT00650208·27 enrolled

Show 4 more trials

Lamotrigine 25 mg Chewable Tablets, Fasting

Completed· Teva logo

Teva·Phase 1·NCT00838279·32 enrolled

An Open-Label Study Of Lamictal In Neurotic Excoriation

Completed·UUniversity of Minnesota·Phase 2·NCT00269594·25 enrolled

Food Study of Lamotrigine Tablets 25 mg to Lamictal® Tablets 25 mg

Completed· Mylan Pharmaceuticals Inc logo

Mylan Pharmaceuticals Inc·Phase 1·NCT00647751·28 enrolled

Lamotrigine 25 mg Chewable Tablets, Non-Fasting

Completed· Teva logo

Teva·Phase 1·NCT00838136·32 enrolled

Fasting Conditions3 trials

Bioequivalence Study of 200 mg Lamotrigine Tablet Under Non-Fasting Conditions

Completed· Teva logo

Teva·Phase 1·NCT00835263·32 enrolled

Bioequivalence Study of 200 mg Lamotrigine Tablet Under Fasting Conditions

Completed· Teva logo

Teva·Phase 1·NCT00834561·32 enrolled

A Bioequivalence Study of Two Formulations Lamotrigine 100 mg Tablets and Lamictal 100 mg Tablets in Healthy Adult Volunteers Under Fasting Conditions

Completed·PPharmtechnology LLC·Phase 1·NCT03898011·28 enrolled

Epilepsy2 trials

Clinical Evaluation of BW430C in Epilepsy

Completed· GSK logo

GSK·Phase 3·NCT00395694·102 enrolled

Clinical Study of Lamotrigine to Treat Newly Diagnosed Epilepsy

Completed· GSK logo

GSK·Phase 3·NCT01431963·70 enrolled

Seizure2 trials

Clinical Study of Lamotrigine to Treat Newly Diagnosed Typical Absence Seizure in Children and Adolescents

Completed· GSK logo

GSK·Phase 3·NCT01431976·20 enrolled

Study Evaluating LAMICTAL Extended-Release Therapy Added To Current Seizure Treatments In Patients With Partial Seizures

Completed· GSK logo

GSK·Phase 3·NCT00113165·244 enrolled

Bipolar I Disorder1 trial

Lamictal as Add-on Treatment for Bipolar I Disorder in Pediatric Patients

Completed· GSK logo

GSK·Phase 3·NCT00723450·301 enrolled

3 more indications

Trigeminal Neuralgia1 trial

Efficacy and Safety Study of Lamotrigine to Treat Trigeminal Neuralgia

Completed·UUniversity of Malaya·Phase 2/3·NCT00913107·21 enrolled

Pregnant Women1 trial

A Pilot Study of Prophylactic Management of Lamotrigine in Pregnant Women

Completed·JJohns Hopkins University··NCT03774641·10 enrolled

Double-blind1 trial

Double-Blind Lamictal (Lamotrigine) in Neurotic Excoriation

Completed·UUniversity of Chicago·Phase 2·NCT00513019·35 enrolled

Sources

References

[1]
ClinicalTrials.gov — 18 trial records for Lamictal. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lamictal compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lamictal. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: GSK

Lamictal

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

LAM7 trials

Fasting Conditions3 trials

Epilepsy2 trials

Seizure2 trials

Bipolar I Disorder1 trial

Trigeminal Neuralgia1 trial

Pregnant Women1 trial

Double-blind1 trial

References

Drug Info

Quick Facts

Related News